Deletions in this region are typical in patients with DiGeorge syndrome.[30] The role of CRKL in oncogenesis has been elucidated in recent years.[31] CRKL amplification is the most common mechanism leading to pathway dysregulation and it has been identified in different tumor types. This evidence concerns the gene CRKL and 22q11.2 deletion syndrome.